

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1. (Original) A composition comprising a multispecific ligand comprising at least a first ligand binding moiety which specifically binds to a first ligand having a first biodistribution and a second ligand binding moiety which specifically binds to a second ligand having a second biodistribution different from that of the first ligand, and wherein the affinity of the first and second ligand binding moieties are different and selected to bias the biodistribution of the multispecific ligand.

Claim 2. (Original) The composition according to claim 1, further comprising a physiologically acceptable excipient.

Claim 3. (Original) The composition according to claim 2, wherein the multispecific ligand comprises a bispecific antibody.

Claim 4. (Original) The composition according to claim 3, wherein the affinity of said first ligand binding moiety for the first ligand is higher than the affinity of the second ligand binding moiety for the second ligand and wherein the biodistribution of the multispecific ligand favours the first ligand.

Claim 5. (Original) The composition according to claim 4, wherein the first and second ligands have overlapping biodistributions.

Claim 6. (Original) The composition according to claim 5, wherein the first ligand is present on a first target cell population and wherein said second ligand is present on a second target cell population comprising the first target cell population and

wherein the biodistribution of the multispecific ligand favours the first target cell population.

Claim 7. (Currently Amended) The composition according to claim 1 ~~or~~ 3, wherein said first ligand is a cell surface marker associated with one or more specific cell populations, infectious or parasitic agents, diseased cells, or disease-associated cells.

Claim 8. (Original) The composition according to claim 7, wherein said marker is an antigen.

Claim 9. (Original) The composition according to claim 7, wherein said marker is an epitope.

Claim 10. (Original) The composition according to claim 7, wherein said marker is a CD marker.

Claim 11. (Original) The composition according to claim 10, wherein said marker is CD4.

Claim 12. (Original) The composition according to claim 7, wherein said marker is specifically associated with a cancer cell or pre-cancerous cell.

Claim 13. (Currently Amended) The composition according to claim 11 ~~or~~ 12, wherein said second ligand is a CCR5 or CXCR4 receptor.

Claim 14. (Original) The composition according to claim 7, wherein said marker is associated with an immune cell that is susceptible to viral infection.

Claim 15. (Original) The composition according to claim 7, wherein said marker is specifically associated with an autoimmune disorder or rheumatic disease.

Claim 16. (Original) The composition according to claim 7, wherein said marker is associated with a specific tissue type.

Claim 17. (Original) The composition according to claim 7, wherein said marker is associated with a specific organ.

Claim 18. (Original) The composition according to claim 7, wherein said marker is associated with a cell or tissue of specific origin or class.

Claim 19. (Original) The composition according to claim 7, wherein said marker is an MHC-peptide complex.

Claim 20. (Original) The composition according to claim 7, wherein said marker is a cell surface immunoglobulin.

Claims 21-130 (Cancelled)